Anagrelide
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Anagrelide: From Essential Thrombocythaemia to Reactive Thrombocytosis
One-Sentence Summary
Anagrelide is a platelet-lowering agent established globally for the management of clonal thrombocytosis, principally essential thrombocythaemia (ET) and related myeloproliferative disorders. The TxGNN model predicts it may be effective for Reactive Thrombocytosis, with 0 clinical trials and 10 publications currently identified in support of this direction. However, the available literature consistently characterises reactive thrombocytosis as a self-limiting, secondary condition for which current EHA and NCCN guidelines explicitly advise against cytoreductive therapy, raising significant questions about the clinical validity of this repurposing prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from UK regulatory data; globally established for essential thrombocythaemia / myeloproliferative disorders |
| Predicted New Indication | Reactive Thrombocytosis |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L3 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this Evidence Pack. Based on information drawn from the supporting literature (PMID 15270658), anagrelide is a phosphodiesterase 3 (PDE3) inhibitor that selectively interferes with megakaryocyte maturation and differentiation, thereby reducing platelet production. It does not act as a conventional cytotoxic agent but rather targets the terminal stages of thrombopoiesis. This mechanism is the established basis for its use in clonal thrombocytosis, where uncontrolled platelet overproduction carries a genuine thrombohemorrhagic risk.
The TxGNN model’s prediction likely identifies a pharmacological overlap: both essential thrombocythaemia and reactive thrombocytosis share the phenotype of elevated platelet count, and anagrelide demonstrably lowers platelets regardless of aetiology. The knowledge graph may therefore draw a structural similarity between the two conditions. Several review articles in the evidence set (PMIDs 15270658, 16019501, 10494240) explicitly discuss reactive thrombocytosis as a key differential diagnosis when managing ET, further reinforcing the conceptual link captured by the model.
However, this is precisely where the mechanistic argument breaks down. Reactive thrombocytosis is a secondary, physiologically driven response to an underlying trigger — most commonly infection, inflammation, iron-deficiency anaemia, or post-splenectomy state — and platelet counts typically normalise once the precipitating cause is treated. Unlike clonal disease, reactive thrombocytosis does not confer the same thrombotic risk, and current clinical guidelines (EHA, NCCN) explicitly recommend against cytoreductive therapy in this setting. The repurposing rationale is therefore mechanistically plausible in isolation but clinically unsound under current standard-of-care frameworks.
Clinical Trial Evidence
Currently no related clinical trials registered for anagrelide in reactive thrombocytosis (ClinicalTrials.gov and ICTRP searched 26 March 2026; 0 results).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15270658 | 2004 | Narrative Review (Mechanisms) | Expert Review of Anticancer Therapy | Comprehensive profile of anagrelide’s PDE3-inhibitory mechanism and role in clonal thrombocytosis; distinguishes reactive from clonal disease and notes reactive thrombocytosis requires no pharmacological intervention |
| 16019501 | 2005 | Critical Review | Leukemia & Lymphoma | Critically evaluates anagrelide evidence base in ET; reinforces that cytoreduction is not warranted in reactive thrombocytosis and that hydroxyurea remains the only RCT-supported agent in high-risk ET |
| 28380402 | 2017 | Review | Leukemia Research | Reviews role of thrombocytapheresis and medical cytoreduction in hyperthrombocytosis within myeloproliferative neoplasms; anagrelide discussed as a medical cytoreductive option but only in clonal disease |
| 10494240 | 1999 | Review | Medical Journal of Australia | Overview of ET diagnosis and management; describes reactive thrombocytosis as a key exclusion criterion and highlights that platelet-lowering therapy (including anagrelide) is reserved for clonal disorders with high platelet counts |
| 38455691 | 2024 | Case Report | European Journal of Case Reports in Internal Medicine | Reports acute myocardial infarction in an ET patient on anagrelide; underscores cardiovascular risk monitoring requirements and the complex thrombotic milieu in myeloproliferative disease |
| 17171694 | 2007 | Retrospective Cohort | Pediatric Blood & Cancer | Retrospective analysis of 12 paediatric cases distinguishing ET from reactive thrombocythemia; highlights the diagnostic challenge and confirms reactive cases required no cytoreductive treatment |
| 1994734 | 1991 | Retrospective Review | American Journal of the Medical Sciences | Characterises the full clinical spectrum of thrombocytosis; discusses cytokine-driven megakaryocyte regulation and identifies reactive thrombocytosis as a distinct, typically self-resolving entity |
| 27276864 | 2016 | Case Report | Srpski Arhiv za Celokupno Lekarstvo | First reported case of ET co-existing with ankylosing spondylitis treated with anagrelide plus DMARDs; reactive mild thrombocytosis in the spondylitis was not separately targeted |
| 29851840 | 2018 | Case Report | Medicine | Describes post-splenectomy reactive thrombocytosis managed perioperatively during digital replantation; no cytoreductive drug used — platelet monitoring and anticoagulation guided care |
| 7783354 | 1995 | Review | Japanese Journal of Clinical Hematology | Japanese clinical review of ET diagnosis and treatment listing anagrelide amongst cytoreductive options; differential from reactive thrombocytosis emphasised as prerequisite before initiating therapy |
UK Market Information
No marketing authorisations have been identified for Anagrelide in the UK within this Evidence Pack. The market status is recorded as Not Marketed with zero MHRA licences on file.
Note: Clinicians should verify current UK authorisation status directly with the MHRA Product Licence register and the BNF/NICE Evidence portal, as this Evidence Pack reflects data as of 4 April 2026 and may not capture all licensing activity.
Safety Considerations
No safety data (key warnings, contraindications, or drug interactions) was available in this Evidence Pack for Anagrelide.
Please refer to the Summary of Product Characteristics (SmPC) and the British National Formulary (BNF) for full safety information. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).
Conclusion and Next Steps
Decision: Hold
Rationale: Although anagrelide’s platelet-lowering mechanism is pharmacologically plausible in any thrombocytotic state, reactive thrombocytosis is a secondary, self-limiting condition in which current EHA and NCCN guidelines explicitly recommend treating the underlying cause rather than deploying cytoreductive agents. The 10 identified publications reinforce this position rather than challenge it — none document a clinical study of anagrelide specifically in reactive thrombocytosis — and zero clinical trials have been registered for this combination. The TxGNN model appears to have identified a phenotypic overlap (elevated platelet count) without accounting for the distinct pathophysiological and risk profile differences between clonal and reactive disease.
To proceed, the following would be needed:
- A compelling mechanistic or epidemiological rationale explaining why anagrelide would offer benefit over simply treating the precipitating cause of reactive thrombocytosis
- Evidence of a reactive thrombocytosis subpopulation (e.g., extreme thrombocytosis post-splenectomy with thrombotic risk) where guidelines permit an exception to the no-cytoreduction rule
- Full MOA data for anagrelide (DrugBank API query recommended to resolve DG002)
- MHRA SmPC data and BNF classification to complete the safety profile (DG001)
- A prospective or retrospective observational study design, should the research question be judged worth pursuing after clinical expert review
Research Use Only. This report is generated for research reference purposes and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All UK use must comply with MHRA regulations.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.